Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome

References

• Hoyle C F, de Bastos M, Wheatley K, et al. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. Br J Haematol 1989; 72: 45–53
   PubMed Web of Science ®Google Scholar
• Oosterveld M, Muus P, Suciu S, et al. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia: two parallel studies adjusted for various prognostic factors. Leukemia 2002; 16: 16151–16621
   Google Scholar
• Graf M, Hecht K, Reif S, et al. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol 2003; 72: 89–106
   Web of Science ®Google Scholar
• te Boekhorst P A, Löwenberg B, Vlastuin M, et al. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia 1993; 7: 1191–1198
   PubMed Web of Science ®Google Scholar
• Te Boekhorst P A, Lo¨wenberg B, Sonneveld P. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. Leukemia 1994; 8: 1480–1486
   PubMed Web of Science ®Google Scholar
• Bai A, Kojima H, Hori M, et al. Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Exp Hematol 1999; 27: 259–265
   PubMed Web of Science ®Google Scholar
• Yamada K, Furusawa S, Saito K, et al. Concurrent use of granulocyte colony stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia 1995; 9: 10–14
   PubMed Web of Science ®Google Scholar
• Qian S X, Li J Y, Tian T, et al. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Leuk Res 2007; 31: 1383–1388
   PubMed Web of Science ®Google Scholar
• Saito K, Nakamura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol 2000; 71: 238–244
   PubMed Web of Science ®Google Scholar
• Takemura Y, Ohnuma T, Chou T C, et al. Biologic and pharmacologic effects of harringtonine on human leukemia–lymphoma cells. Cancer Chemother Pharmacol 1985; 14: 206–210
   PubMed Web of Science ®Google Scholar
• Zhou J Y, Chen D L, Shen Z S, et al. Effect of homoharringtonine on proliferation and differentiation of human leukemic cells in vitro. Cancer Res 1990; 50: 2031–2035
   PubMed Web of Science ®Google Scholar
• Jie H, Donghua H, Xingkui X, et al. Homoharringtonine-induced apoptosis of MDS cell line MUTZ-1 cells is mediated by the endoplasmic reticulum stress pathway. Leuk Lymphoma 2007; 48: 964–977
   PubMed Web of Science ®Google Scholar
• Mai W Y, Lin M F. Induction of apoptosis by homoharringtonine in G1 phase human chronic myeloid leukemic cells. Chin Med J 2005; 118: 487–492
   PubMed Web of Science ®Google Scholar
• Ye X J, Lin M F. Homoharringtonine induces apoptosis of endothelium and down-regulates VEGF expression of K562 cells. J Zhejiang Univ Sci 2004; 5: 230–234
   PubMedGoogle Scholar
• Fresno M, Jimenez A, Vazqueq D. Inhibition of translation in eukaryotic systems by harringtonine. Eur J Biochem 1977; 72: 323–330
   PubMedGoogle Scholar
• Huang M T. Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol 1975; 11: 511–519
   PubMedGoogle Scholar
• Smith C R, Jr, Powell R G, Mikolajczak K L. The genus Cephalotaxus: source of homoharringtonine and related anticancer alkaloids. Cancer Treat Rep 1976; 60: 1157–1170
   PubMedGoogle Scholar
• Cephalotaxus Research Coordinating Group. Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin Med J 1976; 2: 263–272
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Keating M J, Walters R S, et al. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 1989; 63: 813–817
   PubMed Web of Science ®Google Scholar
• Feldman E, Arlin Z, Ahmed T, et al. Homoharringtonine is safe and effective for patients with acute myelogenous leukemia. Leukemia 1992; 6: 1185–1188
   PubMed Web of Science ®Google Scholar
• Feldman E, Arlin Z, Ahmed T, et al. Homoharringtonine in combination with cytarabine for patients with acute myelogenous leukemia. Leukemia 1992; 6: 1189–1191
   PubMed Web of Science ®Google Scholar
• Feldman E J, Seiter K P, Ahmed T, et al. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia. Leukemia 1996; 10: 40–42
   PubMed Web of Science ®Google Scholar
• Fanucchi M P, Kong X R, Chou T C. Hexamethylene bisacetamide(HMBA) does not enhance the cytotoxic effects of adriamycin (ADR), 1,b-d-arabinofuranosylcytosine (ARA-C) and harringtonine (HT) in HL-60 cells [Abstract 1492]. Proc Am Assoc Cancer Res 1986; 27: 376
   Web of Science ®Google Scholar
• Löwenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003; 349: 743–752
   PubMed Web of Science ®Google Scholar
• Delacretaz F, Schmidt P M, Piguet D, et al. Histopathology of myelodysplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsy. Am J Clin Pathol 1987; 87: 180–186
   PubMed Web of Science ®Google Scholar
• ISCN (International System for Human Cytogenetic Nomenclature). Guidelines for cancer cytogenetics. Supplement to an International System for Human Cytogenetic Nomenclature, F Mitelman. Karger, Basel 1991; 1–53
   Google Scholar
• Greenberg P, Cox C, LeBeau M M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
   PubMed Web of Science ®Google Scholar
• Cheson B D, Greenberg P L, Bennett J M, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419–425
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Kopecky K J, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642–4649
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Estey E H, Thall P F, Pierce S, et al. Randomized phase II study of fludarabine = cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999; 93: 2478–2484
   PubMed Web of Science ®Google Scholar
• Hamblin T J. Intensive chemotherapy in myelodysplastic syndromes. Blood Rev 1992; 3: 215–219
   Web of Science ®Google Scholar
• Jackson G, Taylor P, Smith G M, et al. A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol 2001; 112: 127–137
   PubMed Web of Science ®Google Scholar
• Li J M, Shen Y, Wu D P, et al. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients. Int J Hematol 2005; 82: 48–54
   PubMed Web of Science ®Google Scholar